Does REGORAFENIB Cause Carcinoembryonic antigen increased? 91 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 91 reports of Carcinoembryonic antigen increased have been filed in association with REGORAFENIB (Stivarga). This represents 1.0% of all adverse event reports for REGORAFENIB.
91
Reports of Carcinoembryonic antigen increased with REGORAFENIB
1.0%
of all REGORAFENIB reports
10
Deaths
13
Hospitalizations
How Dangerous Is Carcinoembryonic antigen increased From REGORAFENIB?
Of the 91 reports, 10 (11.0%) resulted in death, 13 (14.3%) required hospitalization.
Is Carcinoembryonic antigen increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for REGORAFENIB. However, 91 reports have been filed with the FAERS database.
What Other Side Effects Does REGORAFENIB Cause?
Off label use (1,906)
Fatigue (1,530)
Palmar-plantar erythrodysaesthesia syndrome (1,230)
Diarrhoea (1,221)
Decreased appetite (941)
Asthenia (825)
Death (813)
Dysphonia (702)
Nausea (688)
Pain in extremity (686)
What Other Drugs Cause Carcinoembryonic antigen increased?
RIBOCICLIB (143)
LETROZOLE (115)
CAPECITABINE (113)
FULVESTRANT (105)
BEVACIZUMAB (102)
OXALIPLATIN (88)
OSIMERTINIB (82)
PALBOCICLIB (78)
FLUOROURACIL (71)
PANITUMUMAB (69)
Which REGORAFENIB Alternatives Have Lower Carcinoembryonic antigen increased Risk?
REGORAFENIB vs REGORAFENIB\REGORAFENIB
REGORAFENIB vs RELATLIMAB
REGORAFENIB vs RELPAX
REGORAFENIB vs RELUGOLIX
REGORAFENIB vs REMDESIVIR